INmune Bio Inc (INMB) Stock Forecast & Price Target
INmune Bio Inc · NASDAQ
$2.45-0.06 (-2.39%)
15-min delayed · Sep 9, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering INmune Bio Inc, 1 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $9.00 to $9.00, so the covering firms are broadly aligned. The average target of $9.00 sits 267% above the current $2.45. Sentiment has drifted a little more constructive lately, with Sell ratings easing from 1 to 0 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.17 next quarter toward $-0.49 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Strong Buy
Strong Buy00%
Buy1100%
Hold00%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to INmune Bio Inc.
As of Sep, 1 of 1 firms rate INMB a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
INMB EPS & revenue forecast
EPS · NEXT QUARTER
$-0.17
Range $-0.21 – $-0.14 · 2 analysts · -3% YoY
Next period, 2 analysts expect INmune Bio Inc to earn $-0.17 a share (range $-0.21 – $-0.14), versus $-0.18 a year earlier. Full-year consensus is $-0.55, growing to $-0.49 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 2 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $6.4M next year.
Top analysts covering INmune Bio Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on INMB.
#1
George Farmer
Scotiabank · Rank #240
Sell
$0.60-75.5% to target
Overall win rate
44%
+ Follow
#2
Jason McCarthy
Maxim Group · Rank #428
Buy
$8.00+226.5% to target
Overall win rate
32%
+ Follow
#3
James Molloy
Alliance Global Partners · Rank #454
Buy
$7.00+185.7% to target
Overall win rate
25%
+ Follow
#4
Thomas Shrader
BTIG
Hold
No targeton INMB
Coverage
—
+ Follow
#5
Elemer Piros
Lucid Capital
Buy
$9.00+267.3% to target
Coverage
—
+ Follow
INMB stock forecast FAQ
What is INMB's average 12-month price target?+
The 1 analysts with a live target average $9.00 for INmune Bio Inc over the next 12 months, ranging from a $9.00 high to a $9.00 low.
Is INMB stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 1 analyst ratings, 1 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover INMB?+
1 analysts have an active rating on INmune Bio Inc, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering INMB?+
Among analysts who currently cover INMB, George Farmer of Scotiabank has the strongest overall Quantellect track record (Rank #240). Their current call is Sell with a $0.60 target.
What is INmune Bio Inc's projected EPS for next quarter?+
The consensus estimate is $-0.17 per share (range $-0.21 – $-0.14) across 2 analysts. Full-year EPS is projected at $-0.55, rising to $-0.49 the following year.
How much revenue is INmune Bio Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $6.4M next year.
Have analysts been upgrading or downgrading INMB lately?+
As of Sep, 1 of 1 firms rate INMB a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their INMB calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
